For nearly 4 years now, we pharma marketing aficionados and FDA watchers have been anxiously awaiting the promised guidelines on regulating pharmaceutical promotions on the Internet and social media. Most of us believe we will never see these guidelines in our lifetimes (see here).
My "FDAdar" was aroused, therefore, when I read a Bloomberg story (here) that bluntly stated "[A proposed FDA study of teens and direct-to-consumer (DTC) advertising] will help determine whether some drugs may require more carewhen advertising online [my emphasis], the FDA said."
I searched the document announcing this study in the Federal Register (here) and could not find the word "online" mentioned.
But wait! Upon further careful reading of the FDA study design protocol, I found this..
No comments:
Post a Comment